PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
Sagun Parakh, Ashan Musafer, Sabrina Paessler, Tom Witkowski, Connie SN Li Wai Suen, Candani SA Tutuka, Matteo S Carlino, Alexander M Menzies, Richard A Scolyer, Jonathan Cebon, Alexander Dobrovic, Georgina V Long, Oliver Klein, Andreas Behren
FRONTIERS IN IMMUNOLOGY | FRONTIERS MEDIA SA | Published : 2021
A significant number of patients (pts) with metastatic melanoma do not respond to anti-programmed cell death 1 (PD1) therapies. Identifying predictive biomarkers therefore remains an urgent need. We retrospectively analyzed plasma DNA of pts with advanced melanoma treated with PD-1 antibodies, nivolumab or pembrolizumab, for five PD-1 genotype single nucleotide polymorphisms (SNPs): PD1.1 (rs36084323, G>A), PD1.3 (rs11568821, G>A), PD1.5 (rs2227981, C>T) PD1.6 (rs10204225, G>A) and PD1.9 (rs2227982, C>T). Clinico-pathological and treatment parameters were collected, and presence of SNPs correlated with response, progression free survival (PFS) and overall survival (OS). 115 patients were ide..View full abstract
Awarded by National Health and Medical Research Council of Australia (NHMRC)
This work was supported by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia and Melanoma Research Victoria (MRV). AMM is supported by a Cancer Institute NSW Fellowship. A. Behren is the recipient of a Fellowship from the Victorian Government Department of Health and Human Services acting through the Victorian Cancer Agency. We would like to thank Sudheer Veduruparthi for his assistance in SNP genotyping. RS is supported by a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1093017) and Practitioner Fellowship (APP1141295).